Company profile: Nurix Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics and discovery via the DELigase platform leveraging E3 ligases and DNA-encoded libraries for targeted protein degradation (TPD) and elevation (TPE). Pipeline includes oral candidates NX-5948 (BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor) for B-cell malignancies, solid tumors, and autoimmune diseases.
Products and services
- Targeted Protein Degradation: An ubiquitin-based modality that engineers small molecules which bind E3 ligases and target proteins, facilitating ubiquitin transfer onto targets to drive selective degradation
- Targeted Protein Elevation: A ligase-selective approach using small molecules to inhibit specific E3 ligases, increasing levels of beneficial proteins and enabling a novel path to treat diverse diseases
- DELigase Platform: A DNA-encoded discovery engine that leverages E3 ligases and DNA-encoded libraries to identify small molecules for targeted protein modulation, spanning degradation and elevation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nurix Therapeutics
Jnana Therapeutics
HQ: United States
Website
- Description: Provider of chemoproteomics-driven drug discovery via its RAPID platform to identify small-molecule medicines for a range of diseases; developing JNT-517, an allosteric SLC6A19 inhibitor for phenylketonuria to reduce plasma phenylalanine; advancing programs for autoimmune and inflammatory conditions; and collaborating with biopharma in cancer, immune-mediated, and neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jnana Therapeutics company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
Recordati
HQ: Italy
Website
- Description: Provider of medications and treatment options across specialty and primary care, consumer healthcare, and rare diseases, focusing on the development and distribution of therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recordati company profile →
Alltrna
HQ: United States
Website
- Description: Provider of a tRNA therapeutics platform that uses machine learning and high-throughput proprietary in vitro assays to design and optimize therapeutic tRNA molecules for diseases with genetic mutations. Solutions include tRNA medicines that read stop codons to restore full-length protein production, with data-integrated workflows to refine predictive design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alltrna company profile →
Lin Bioscience
HQ: Taiwan
Website
- Description: Provider of innovative drug therapies addressing unmet medical needs, developing: LBS-008, an oral treatment for dry age-related macular degeneration and Stargardt disease; LBS-007, a CDC7 inhibitor for leukemia and solid tumors; LBS-002, an anti-tubulin therapy for brain tumors that crosses the blood-brain barrier; and LBS-009, an oral therapy for NAFLD and type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lin Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nurix Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nurix Therapeutics
2.2 - Growth funds investing in similar companies to Nurix Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nurix Therapeutics
4.2 - Public trading comparable groups for Nurix Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →